20240010602. PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES simplified abstract (Xavier University of Louisiana)
Contents
- 1 PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Original Abstract Submitted
PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES
Organization Name
Xavier University of Louisiana
Inventor(s)
Rami A. Al-horani of New Orleans LA (US)
PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240010602 titled 'PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES
Simplified Explanation
The present disclosure is about compounds and their enantiomers, which can be used for the treatment of thrombosis and related conditions and complications. The patent application provides the formula and definitions of various variables used in the compounds. It also includes information on pharmaceutical compositions containing these compounds.
- The patent application is about compounds and their enantiomers.
- The compounds have a specific formula and definitions for various variables.
- The compounds can be used for the treatment of thrombosis and related conditions.
- The patent application also covers pharmaceutical compositions containing these compounds.
Potential Applications
- Treatment of thrombosis and related conditions
- Prevention of thrombosis in high-risk individuals
- Management of complications associated with thrombosis
Problems Solved
- Lack of effective treatment options for thrombosis and related conditions
- Limited prevention strategies for individuals at high risk of thrombosis
- Inadequate management of complications arising from thrombosis
Benefits
- Novel compounds with potential therapeutic applications
- Improved treatment options for thrombosis and related conditions
- Enhanced prevention strategies for individuals at risk of thrombosis
- Better management of complications associated with thrombosis
Original Abstract Submitted
the present disclosure is directed to compounds having formula (i) and their enantiomers, wherein the definitions of r, y, y, w, x, z, and n are provided in the disclosure. the disclosure is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use for treatment of thrombosis and related conditions and complications.
